Literature DB >> 25049265

Transoral robotic versus open surgical approaches to oropharyngeal squamous cell carcinoma by human papillomavirus status.

Samuel E Ford1, Margaret Brandwein-Gensler2, William R Carroll3, Eben L Rosenthal3, J Scott Magnuson4.   

Abstract

OBJECTIVES: (1) Investigate oncologic survival outcomes and (2) analyze the impact of human papillomavirus status on prognosis in patients with oropharyngeal squamous cell carcinoma treated with transoral robotic versus open surgery. STUDY
DESIGN: Retrospective cohort study.
SETTING: Tertiary care referral center, University of Alabama at Birmingham Hospital.
SUBJECTS: One hundred thirty total (65 per treatment arm) with primary oropharyngeal squamous cell carcinoma (OPSCC).
METHODS: Patients treated for primary oropharyngeal squamous cell carcinoma with either transoral robotic (TORS) or open surgery plus standard of care adjuvant therapy between October 2004 and March 2012 were matched based on TNM staging before a retrospective chart review was performed. Carcinoma tissue was stained both prospectively and retrospectively with CINtec p16-INK4a kits for surrogate human papillomavirus typing. Recurrence-free survival was used to evaluate the impact of human papillomavirus tumor status and method of surgical intervention on prognosis.
RESULTS: As a whole, patients treated with transoral robotic surgery survived more frequently (94%, 91%, 89% at 1, 2, 3 years, respectively) than those treated with open surgery (85%, 75%, 73% at 1, 2, 3 years, correspondingly) (P = .035). The subgroup of patients with human papillomavirus-negative malignancies treated with open surgery survived without recurrence less frequently at 1, 2, and 3 year rates of 58%, 25%, 25%, respectively (P < .01).
CONCLUSION: These retrospective data suggest that oncologic outcomes are not being sacrificed when patients with OPSCC are treated with TORS instead of open surgery regardless of tumor human papillomavirus immunohistochemical staining. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2014.

Entities:  

Keywords:  HPV; TORS; carcinoma; human papillomavirus; oropharynx; p16; p16-INK4a; robotic; surgery; survival; transoral

Mesh:

Year:  2014        PMID: 25049265     DOI: 10.1177/0194599814542939

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  11 in total

1.  Classification system for lateral pharyngotomy: systematic study of anatomic exposure in a human cadaver model.

Authors:  Courtney Shires; Aaron Smith; Jenn Lee; John Boughter; Merry Sebelik
Journal:  Surg Radiol Anat       Date:  2017-02-27       Impact factor: 1.246

2.  Transoral robotic surgery vs open surgery in head and neck cancer. A systematic review of the literature.

Authors:  À Roselló; R Albuquerque; X Roselló-Llabrés; A Marí-Roig; A Estrugo-Devesa; J López-López
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2020-09-01

Review 3.  The Role of Transoral Robotic Surgery in the Management of HPV Negative Oropharyngeal Squamous Cell Carcinoma.

Authors:  Ryan Sload; Natalie Silver; Basit Abjul Jawad; Neil D Gross
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.075

Review 4.  Transoral robotic surgery and intensity-modulated radiotherapy in the treatment of the oropharyngeal carcinoma: a systematic review and meta-analysis.

Authors:  Armando De Virgilio; Andrea Costantino; Giuseppe Mercante; Raul Pellini; Fabio Ferreli; Luca Malvezzi; Giovanni Colombo; Giovanni Cugini; Gerardo Petruzzi; Giuseppe Spriano
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-07-21       Impact factor: 2.503

5.  Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early-Stage Oropharyngeal Squamous Cell Carcinoma.

Authors:  Anthony T Nguyen; Michael Luu; Jon Mallen-St Clair; Alain C Mita; Kevin S Scher; Diana J Lu; Stephen L Shiao; Allen S Ho; Zachary S Zumsteg
Journal:  JAMA Oncol       Date:  2020-10-01       Impact factor: 31.777

6.  Impact of surgical margins on local control in patients undergoing single-modality transoral robotic surgery for HPV-related oropharyngeal squamous cell carcinoma.

Authors:  Andrew J Holcomb; Matthew Herberg; Madeleine Strohl; Edgar Ochoa; Allen L Feng; Nicholas B Abt; Tara E Mokhtari; Krish Suresh; Christopher I McHugh; Anuraag S Parikh; Peter Sadow; William Faquin; Daniel Faden; Daniel G Deschler; Mark A Varvares; Derrick T Lin; Carole Fakhry; William R Ryan; Jeremy D Richmon
Journal:  Head Neck       Date:  2021-04-15       Impact factor: 3.821

Review 7.  Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer.

Authors:  Sonia N Whang; Maria Filippova; Penelope Duerksen-Hughes
Journal:  Viruses       Date:  2015-09-17       Impact factor: 5.048

8.  Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients.

Authors:  Kate Clancy; Chelsea S Hamill; W Quinn O'Neill; Brandon Vu; Jason Thuener; Shanying Gui; Shawn Li; Nicole Fowler; Rod Rezaee; Pierre Lavertu; Jay Wasman; Monaliben Patel; Hira Shaikh; Eric Vick; Anant Madabhushi; Trisha M Wise-Draper; Kyunghee Burkitt; Theodoros N Teknos; Quintin Pan
Journal:  Cancers (Basel)       Date:  2021-09-28       Impact factor: 6.575

9.  Long-term Functional and Quality-of-Life Outcomes After Transoral Robotic Surgery in Patients With Oropharyngeal Cancer.

Authors:  Virginie Achim; Rachel K Bolognone; Andrew D Palmer; Donna J Graville; Tyler J Light; Ryan Li; Neil Gross; Peter E Andersen; Daniel Clayburgh
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-01-01       Impact factor: 6.223

Review 10.  Transoral robotic surgery for oropharyngeal cancer: patient selection and special considerations.

Authors:  R Michael Baskin; Brian J Boyce; Robert Amdur; William M Mendenhall; Kathryn Hitchcock; Natalie Silver; Peter T Dziegielewski
Journal:  Cancer Manag Res       Date:  2018-04-20       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.